Sterols and sterolins in Hypoxis hemerocallidea (African potato) by Nair, V D P & Kanfer, I
pH range for all mixtures, confirming the role played by the hydrolysis of
the AMD components: Fe3+, Fe2+ and Al3+ undergo hydrolysis in the
pH range 4–722 and the buffer region in these experiments was observed
at pH 4.5–7. Another important observation was that the time taken to
overcome the buffer region was inversely proportional to the amount of
FA in the mixture: for the AMD:FA ratios 2:1 and 3:1 the buffer region
lasted for nearly 120 minutes whereas for mixtures 4:1 and 10:1 the corre-
sponding time was nearly 240 minutes (Fig. D). In the case of the 100:1 to
20:1 mixtures, the FA did not provide enough alkalinity to increase the
pH of the solution to overcome this pH plateau in the reaction time
tested.
The observed pH plateau indicate that after an initial stoichiometric
neutralization, leading to an increase in pH to 4.5–6.5, the AMD compo-
nents hydrolysed in the buffer zone, before the residual alkalinity of the
FA allowed a further increase of pH. In addition, FA particles become
coated (‘armoured’) with Fe and Al oxyhydroxides in the buffer region,
preventing the neutralization reaction based on readily soluble species
from continuing.33 The later pH increase may indicate that FA continued
to release substantial alkalinity via the slow dissolution of its glassy
phases.34 Abrasion of particles during continuous stirring may have
enhanced this alkalinity release.35 Three factors thus seemed to dictate
the pH and nature of the final solution obtained, namely, the amount
of FA in relation to the volume of AMD, the quantity of hydrolysable
constituents available in the AMD, and the reaction time.
The variation of EC with time during neutralization reactions
Figure E online shows the variation in EC with time for different AMD:
FA mixtures. High ratios (100:1 to 10:1) did not show any significant
reduction in EC in the final water, as values remained between 7 and
9 mS/cm. This can be attributed mainly to the fact that, at such ratios, the
pH did not exceed 5.5, and most AMD constituents remained in solution.
Another factor may be the small amounts of FA added, so that the soluble
species that would be released from the ash and thus their availability for
reaction, were minimal. Ratios 4:1 to 2:1 showed a steady decrease in EC
as contaminant species were removed from solution by precipitation or
adsorption onto FA particles. For the lowest ratio (1:1), after a steep EC
decrease in the first 30–60 minutes, a slight increase occurred. This can be
attributed to the high FA content in the reaction mixture.
The factor that could lead to enhanced EC at high FA content was the
dissolution of soluble salts on the surface of ash particles and dissolution
of unreacted CaO, which contributed to increased concentration of
unreacted OH– ions.
This article is accompanied by supplementary figures and tables online
at www.sajs.co.za
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Introduction
African potato (AP), Hypoxis hemerocallidea, apart from its
perceived nutritional value, is of active medical interest, and is
purported by many South Africans as possibly being the
best-known medicinal plant. Although African potato is the
common name, its underground growth is not a tuber, but a
corm. Furthermore, the term African potato is also, and confus-
ingly, attributed to another plant, Plectrantus esculentus. The
name Hypoxis will therefore be used throughout this text when
referring to the AP. Extracts of the corms have been ingested by
man as a dietary supplement and for a diversity of ailments.1–6 In
recent years, the increasing interest in functional foods and the
use of phytosterols, their glycosides (sterolins) and steryl esters
(>2 g/day) for reducing serum cholesterol and increasing
immunity has resulted in these compounds regaining consider-
able attention.1 There are many herbal formulations containing
sterols for this reason, most of which have been fortified with
additional amounts of free sterols, stanols and sterolins. Com-
mercially available health supplements and herbal remedies
containing sterols and sterolins as well as Hypoxis, alone or
enriched with sterols and sterolins, are claimed to be efficacious
for a variety of ailments. In particular, purported sterol and
sterolin content in products containing Hypoxis is identified to
be the important feature for the therapeutic claims of these
products.
Sterols and stanols are claimed to play an important role in the
realm of health supplements, with extensive scientific argument
for their prophylactic and therapeutic use for various medical
conditions and ailments, such as atherosclerosis,2,3 benign
prostatic cancer4 and colon cancer.5, 6 However, many reports on
the medicinal properties of sterols are largely based on in vitro
analyses or unrealistic high in vivo dosages, making the thera-
peutic claims for these compounds disputable.
The average daily human dietary consumption of phytosterols
is approximately 250 mg, mostly derived from vegetable oils,
cereals, fruits and vegetables.7 Dietary phytosterols have been
estimated to be almost twice this intake in the case of vegetarians.
Phytostanols are much less abundant in nature than phyto-
sterols and are consequently consumed in relatively lower
amounts (c. 25 mg/day) in human diets.1 Phytosterols have also
been used since the mid-1990s in strategies for lowering choles-
terol, and for reducing the risk of cardiovascular diseases (CVD).
The advent of the ‘statin’ compounds has resulted in a rapidly
diminished use of phytosterol products. Lipophilic extracts of
Hypoxis corms have been used in Europe for the treatment of
prostate problems.8 These extracts are claimed to have anti-
inflammatory activity, and to relieve the symptoms of prostate
adenoma. The components claimed to be responsible for this
effect are mixtures of phytosterols, and it is claimed that
Commercially available health supplements and herbal remedies
containing sterols and sterolins, either from African potato
(Hypoxis hemerocallidea) alone, or whether enriched with sterols
and sterolins, are claimed to be efficacious in the treatment of a
variety of ailments. Sterols and sterolins in African potato are
purported to be the relevant constituents that are required for
the therapeutic claims of such products. A patent describing the
extraction of sterolins from African potato plant material has
claimed that approximately 9 mg sterolins can be isolated from
100 g of an enriched aqueous African potato extract. Our analysis of
African potato plant material and its sterol and sterolin content,
when similarly prepared, shows that the measureable content of
sterols and sterolins in African potato is far less than the amounts of
these compounds that have been claimed to be necessary for
therapeutic benefit. We conclude that therapeutic claims relating to
sterol and sterolin content in African potato are unsubstantiated, in
view of the extremely low content of such compounds that we have
isolated from our plant material, and in products containing African
potato, or extracts thereof.
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β-sitosterol (Fig. 1) is the main active compound. A commercial
product, Harzol®, was launched in 1974, and consists of a
combination of b-sitosterol and its glucoside, BSSG (Fig. 2) and
has gained wide acceptance in Germany. The glycosides (includ-
ing BSSG) were purported to be obtained from Hypoxis, and
their action in the treatment of benign prostate hypertrophy
was attributed to inhibition of 5α-reductase, or to diminished
binding of dihydrotestosterone within the prostate gland.9
Various other commercial preparations were subsequently
launched, and were claimed to contain Hypoxis extracts, or other
plant material, specifically for their sterol/sterolin content. One
such formulation, initially purported to contain Hypoxis, was
stated to contain sterols-to-sterolins in the mass ratio of 100:1.
This specific ratio has been claimed to enhance the in vitro
proliferative response of human T cells, more so than individual
sterols at the same concentration, and this claim was used to
market and promote sales of this particular product.5–10 The
Hypoxis component, however, was subsequently removed from
this product, and the included phytosterols have been subse-
quently claimed to be sourced from elsewhere.
With the absence of convincing ethnomedical information
relating to the efficacy of the 100:1 ratio of sterols-to-sterolin,
coupled with the non-availability of data from other sterol and
sterolin ratios, the situation raises doubt regarding the validity of
the efficacy and therapeutic claims for such products. Claims of
phytosterol content in Hypoxis nevertheless continue to be
made, such as a recent advertisement for Santjie Marx Products,
which includes the statement: ‘The plant sterols and sterolins
that are essential to proper immune system function, are highly
concentrated in the Africa Potato plant’ (http://www.smarx-
produkte.com/).
Early claims relating to the medicinal properties of β-sitosterol
and its glycoside in Hypoxis have been reported in the litera-
ture. 1 1 Although not substantiated by definit ive
pharmacological data, several patents have been filed on the us-
age and medicinal claims of sterolin-enriched extracts of Hypoxis
for various therapeutic purposes.12–17 In particular, a patent filed
by Pegel and Liebenberg in 197318 claimed that the potency of an
extract from Hypoxis species in the treatment of prostate
hypertrophy was correlated with chemically non-defined
phytosterol glycosides (sterolins such as BSSG).
It should be noted that due to poor aqueous solubility and
limited bioavailability of free phytosterols, their purported
serum cholesterol-lowering effects were not always found to be
consistent, and very high oral doses (up to 25–50 g/day) appear
to be required for efficacy. The problems of solubility and
bioavailability have led to many contradictory results in early
clinical studies.1
The highest yield recorded in the US patent entitled ‘Extrac-
tion of sterolins from plant material’, was about 9 mg sterolin
from 100 g of an enriched aqueous extract of Hypoxis.17–20 The
extractive value of the above aqueous isolate, defined as the
content of extractable matter in milligrams per gram of plant
material, was not given in the patent. Repeated experiments
with the extraction of Hypoxis, conducted in our laboratories, has
consistently yielded about 30% w/w dried aqueous extract from
fresh corms of Hypoxis. From our data, the patent’s claimed 9 mg
of sterolin (BSSG) in 100 g of aqueous extract of Hypoxis can be
estimated to have originated from about 300 g of fresh Hypoxis
plant material.
Sterolins are deglycosylated to their corresponding sterols in
the gastrointestinal tract (GIT) of humans, following ingestion,
and the resulting sterol is claimed to be responsible for the
purported therapeutic effect.7 Comparing the molecular weight
ratio of BSSG (molecular weight, 552.89) with BSS (molecular
weight, 414.65), 9 mg will stoichiometrically convert to about
6.8 mg β-sitosterol, which is far lower than the reported thera-
peutic dose required for efficacy.7 To date, except for the claims
made in the aforementioned patent, to our knowledge there
have been no research publications describing the isolation and
analysis of sterols or sterolins from Hypoxis. Nor are there any
scientific data to substantiate the amount of these phytoconstit-
uents that is claimed to be required for therapeutic efficacy.
Their presence in adequate therapeutic concentration in any
species of the genus Hypoxis deserves scrutiny. The issue has
been raised by Nicoletti et al.24 and Hostetmann et al.8
Based on our argument, we propose that any nutritional or
therapeutic value of Hypoxis is unlikely to be due to the presence
of sterolins in Hypoxis or extracts therefrom, as final extractive
recovery of these compounds is <0.01% w/w of enriched extract.
Content of sterols and sterolins in Hypoxis
A Hypoxis extract was prepared from Hypoxis plant material,
in accordance with the example procedure recorded in the
patent.16 We measured the content of sterols (β-sitosterol and
stigmasterol) and BSSG recovered. Extractive procedure is
similar to the Hypoxis decoctions prepared according to the
common recipe used by traditional healers (sangomas) in the
Eastern Cape province of South Africa. Analysis involved a
validated HPLC procedure, coupled with evaporative light-
scattering detection for the qualitative and quantitative determi-
nation of sterols and BSSG.25 The aqueous extract did not show
any detectable quantities of BSSG or BSS and this was confirmed
by spiking the sample solutions with known concentrations of
BSS and BSSG standards.
The content of sterols (stigmasterol, β-sitosterol and stigma-
stanol) and sterolins in the preparation outlined above is less
than our analytical detection limit of 0.002%w/w. This equates
to an amount of less than about 6 mg BSSG/100 g of aqueous
extract, in contrast to the content of 9.01 mg/100 g aqueous
extract, as given in the patent information. Notwithstanding the
patent claims, we confirm a lower sterolin content of Hypoxis,
and we show that this so-called enriched extract of Hypoxis con-
tains less than 0.002% sterolins.
We conclude that because the daily consumption by consumers
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Fig. 1. β-Sitosterol (BSS).
Fig. 2. β-Sitosterol glucoside (BSSG).
of Hypoxis is about 200–500 ml of such an aqueous decoction
(typically containing about 37 mg fresh Hypoxis per ml, or c.18.5 g
of Hypoxis plant material),26 the daily intake of BSS and BSSG, if
present in the decoction, will be negligible (about a milligram)
and will be inadequate for any therapeutic efficacy (Table 1).
Health-product preparations of Hypoxis hemerocallidea are
readily available from retail outlets, and more recently via the
internet, and the suppliers and manufacturers of these products
continue to make a variety of claims regarding the efficacy of
such products. It is the purpose of this communication to present
a scientific appraisal of these claims, and to afford evidence that
they are suspect.
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Table 1. Content of sterols and sterolin in African potato.
Sample no. Sample profile Amount
1 Reported analytical profile of AP23 Amount of sterolin (BSSG)/100 g of enriched aqueous extract of AP 9.01 mg
Equivalent amount of sterol (BSS)/100 g enriched aqueous extract 6.8 mg
2 Reported consumption of AP26 Average daily consumption of traditional extract of AP 200–500 ml
Average concentration of fresh AP in typical traditional extract c. 37 mg fresh AP/ml
Calculated average daily consumption of AP through traditional extract 7.5–18.5 g AP material
3 Current analytical method Limit of detection for BSSG 2 µg/ml
Amount of BSSG in 100 mg fresh AP/ml <2 µg/100 mg fresh AP/ml
(<0.002% w/w in fresh AP)
